This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
stem cell | 817 |
mg kg | 644 |
influenza virus | 587 |
cell transplantation | 561 |
study design | 553 |
intensive care | 529 |
case studies | 493 |
background case | 481 |
clinical signs | 471 |
design method | 387 |
results finding | 375 |
influenza viruses | 368 |
acute respiratory | 358 |
bone marrow | 351 |
critically ill | 347 |
public health | 340 |
gene expression | 338 |
median age | 331 |
risk factors | 326 |
statistically significant | 318 |
amino acid | 313 |
care unit | 312 |
critical care | 309 |
hematopoietic stem | 304 |
see table | 302 |
peripheral blood | 295 |
united states | 289 |
septic shock | 284 |
respiratory syndrome | 277 |
immune response | 274 |
patients received | 273 |
ill patients | 273 |
respiratory tract | 263 |
pandemic influenza | 263 |
supplementary table | 261 |
conditioning regimen | 254 |
additional file | 254 |
severe acute | 252 |
overall survival | 251 |
mass spectrometry | 250 |
mechanical ventilation | 249 |
whole blood | 246 |
virus infection | 245 |
significantly higher | 243 |
chronic gvhd | 243 |
red blood | 241 |
high risk | 230 |
cell lines | 228 |
seasonal influenza | 219 |
clinical trials | 213 |
acute gvhd | 212 |
blood pressure | 208 |
two groups | 207 |
cd cells | 205 |
median time | 204 |
host disease | 202 |
one patient | 201 |
blood bank | 196 |
cardiac arrest | 195 |
median follow | 189 |
performed using | 189 |
years old | 186 |
stem cells | 185 |
avian influenza | 184 |
significant difference | 184 |
cell line | 183 |
cell culture | 180 |
control group | 179 |
significant differences | 177 |
infectious diseases | 173 |
patients admitted | 173 |
may also | 170 |
ml kg | 164 |
blood cells | 162 |
allogeneic hematopoietic | 160 |
hong kong | 160 |
mg dl | 159 |
patients undergoing | 159 |
university hospital | 158 |
human sars | 158 |
cord uid | 156 |
doc id | 156 |
respiratory distress | 156 |
free survival | 152 |
mental health | 151 |
cd cd | 150 |
blood cell | 149 |
retrospective study | 148 |
body weight | 148 |
immune system | 146 |
results findings | 144 |
present study | 143 |
gvhd prophylaxis | 143 |
mortality rate | 143 |
blood donors | 142 |
icu admission | 142 |
virus replication | 142 |
kg iv | 140 |
cord blood | 139 |
hospital mortality | 138 |
design methods | 138 |
two patients | 137 |
adult patients | 137 |
amino acids | 137 |
syndrome coronavirus | 137 |
rrt pcr | 136 |
flow cytometry | 134 |
within hours | 133 |
logistic regression | 133 |
viral infections | 132 |
risk factor | 131 |
health care | 130 |
protease inhibitors | 130 |
blood products | 129 |
ng ml | 129 |
mean age | 129 |
least one | 127 |
hiv aids | 123 |
cohort study | 123 |
antiviral activity | 123 |
adverse events | 122 |
bat cov | 122 |
heart failure | 121 |
icu stay | 120 |
multiple myeloma | 120 |
unrelated donor | 120 |
patients receiving | 119 |
icu patients | 119 |
blood center | 118 |
job crafting | 117 |
observational study | 117 |
organ failure | 117 |
blood samples | 117 |
day mortality | 117 |
complete remission | 116 |
multivariate analysis | 116 |
active site | 116 |
increased risk | 116 |
type i | 116 |
respiratory failure | 115 |
cumulative incidence | 114 |
novel coronavirus | 114 |
influenza vaccine | 113 |
sofa score | 112 |
total number | 112 |
immune responses | 112 |
time points | 111 |
human rhinovirus | 110 |
epithelial cells | 110 |
clinical outcomes | 109 |
viral replication | 109 |
viral rna | 108 |
renal failure | 107 |
platelet count | 104 |
allogeneic hsct | 104 |
broccoli sprouts | 103 |
statistical significance | 103 |
red cell | 103 |
cd cell | 102 |
allogeneic stem | 102 |
side effects | 102 |
patients treated | 102 |
slot booking | 101 |
emergency department | 101 |
coronavirus disease | 101 |
graft failure | 100 |
blood group | 100 |
upper respiratory | 99 |
respiratory syncytial | 98 |
nk cells | 98 |
transplant recipients | 98 |
graft versus | 98 |
heart disease | 97 |
medical center | 97 |
pediatric patients | 97 |
viral infection | 97 |
infected cells | 97 |
systematic review | 97 |
myeloid leukemia | 96 |
patients without | 96 |
commonly used | 96 |
nervous system | 96 |
regression analysis | 96 |
clinical trial | 96 |
significantly lower | 95 |
mast cells | 95 |
respiratory viruses | 95 |
swine influenza | 95 |
previous studies | 95 |
previously described | 95 |
syncytial virus | 94 |
central venous | 94 |
acute myeloid | 94 |
important role | 92 |
myeloablative conditioning | 92 |
university spin | 91 |
weight loss | 91 |
lower respiratory | 90 |
marrow transplantation | 90 |
mask mandates | 90 |
fractal dimension | 90 |
nucleic acid | 89 |
lung injury | 89 |
severe covid | 89 |
among patients | 89 |
world health | 88 |
versus host | 88 |
food insecurity | 88 |
study period | 87 |
confidence interval | 87 |
class i | 86 |
rate coefficient | 86 |
blood components | 86 |
blood transfusion | 85 |
innate immune | 85 |
central nervous | 85 |
clinical practice | 84 |
growth factor | 84 |
gene rrt | 84 |
retrospective analysis | 84 |
septic patients | 84 |
coronary artery | 84 |
significantly increased | 84 |
autologous stem | 84 |
supplementary information | 84 |
binding rate | 83 |
activated charcoal | 83 |
reproductive tract | 83 |
human influenza | 83 |
statistical analysis | 83 |
significant increase | 83 |
viral load | 83 |
fractal analysis | 83 |
disease control | 83 |
rbc units | 82 |
days post | 82 |
significantly different | 82 |
heart rate | 82 |
health organization | 82 |
host cell | 82 |
two different | 82 |
high levels | 82 |
regulated proteins | 80 |
brain injury | 80 |
kidney injury | 80 |
ex vivo | 80 |
influenza infection | 80 |
inflammatory response | 80 |
orogastric lavage | 80 |
laser desorption | 79 |
transfusion medicine | 79 |
social media | 79 |
included patients | 79 |
middle east | 79 |
breast cancer | 79 |
previously reported | 79 |
consecutive patients | 78 |
hospital stay | 78 |
wide range | 78 |
adverse effects | 78 |
cardiac surgery | 78 |
table shows | 78 |
significantly associated | 78 |
four patients | 78 |
time point | 77 |
real time | 77 |
informed consent | 77 |
results suggest | 77 |
quality control | 77 |
differentially expressed | 77 |
blood product | 77 |
kg day | 77 |
grade ii | 77 |
blood stem | 77 |
determine whether | 76 |
positive samples | 76 |
related mortality | 76 |
prospective study | 75 |
pulmonary edema | 75 |
blood flow | 75 |
three patients | 75 |
factors associated | 75 |
cell death | 75 |
closely related | 74 |
replacement therapy | 74 |
monoclonal antibodies | 74 |
escherichia coli | 74 |
previously published | 74 |
abdominal pain | 74 |
incubation period | 73 |
disease severity | 73 |
mdck cells | 73 |
within days | 73 |
may occur | 73 |
sars cov | 73 |
pg ml | 73 |
surveillance system | 72 |
critical illness | 72 |
acute kidney | 72 |
reduced intensity | 72 |
intravenous fluids | 72 |
influenza pandemic | 72 |
patients died | 72 |
cell transplant | 71 |
standard deviation | 71 |
class ii | 71 |
water samples | 71 |
distress syndrome | 71 |
reverse transcription | 71 |
cancer cells | 71 |
granted medrxiv | 70 |
antigen expression | 70 |
decision making | 70 |
highly pathogenic | 70 |
tof ms | 70 |
healthy controls | 70 |
author funder | 70 |
blood loss | 69 |
trade credit | 69 |
mortality rates | 69 |
rna viruses | 69 |
also found | 69 |
cmv reactivation | 69 |
chain reaction | 69 |
cell surface | 69 |
room temperature | 69 |
bat species | 69 |
primary outcome | 69 |
age groups | 69 |
conditioning regimens | 68 |
widely used | 68 |
hepatocellular carcinoma | 68 |
apache ii | 68 |
viral proteins | 68 |
desorption ionization | 68 |
dna sequences | 68 |
randomized controlled | 68 |
large number | 68 |
sample size | 68 |
grade iii | 67 |
supplemental oxygen | 67 |
per year | 67 |
per day | 67 |
organ dysfunction | 67 |
protein sequences | 67 |
mouse model | 67 |
antibiotic therapy | 67 |
gastrointestinal tract | 67 |
dna methylation | 66 |
transfusion service | 66 |
kg po | 66 |
guinea pigs | 66 |
physical examination | 66 |
time pcr | 66 |
infection control | 66 |
single center | 66 |
chronic diseases | 66 |
carbon dioxide | 66 |
infectious disease | 66 |
hematopoietic cell | 66 |
peer review | 66 |
high dose | 66 |
crystal structure | 66 |
cho cells | 66 |
infected patients | 66 |
mononuclear cells | 66 |
lung cancer | 66 |
five patients | 65 |
endothelial cells | 65 |
even though | 65 |
high mortality | 65 |
recent years | 64 |
lymph nodes | 64 |
polymerase chain | 64 |
care units | 64 |
mechanically ventilated | 64 |
uncertain linguistic | 64 |
matched unrelated | 64 |
mm hg | 64 |
renal replacement | 63 |
disease status | 63 |
transfusion reactions | 63 |
common cold | 63 |
phylogenetic analysis | 63 |
canine distemper | 63 |
respiratory infections | 63 |
copyright holder | 63 |
binding sites | 62 |
blood volume | 62 |
may help | 62 |
intensity conditioning | 62 |
long term | 62 |
patient care | 62 |
flow rate | 62 |
product quality | 62 |
tract infections | 62 |
arterial blood | 62 |
cell growth | 62 |
reactive protein | 62 |
diabetes mellitus | 62 |
binding affinity | 62 |
age group | 62 |
may lead | 61 |
foreign bodies | 61 |
food insecure | 61 |
positive results | 61 |
virus infections | 61 |
commercially available | 61 |
sars coronavirus | 61 |
severe disease | 61 |
signaling pathways | 61 |
graphical representation | 61 |
also used | 61 |
bacterial infections | 61 |
see section | 61 |
response rate | 61 |
acute leukemia | 61 |
structural proteins | 61 |
version posted | 61 |
analysis showed | 61 |
time period | 60 |
foreign body | 60 |
monoclonal antibody | 60 |
cell density | 60 |
inhibitory activity | 60 |
cell count | 60 |
antibody response | 60 |
one year | 60 |
growth rate | 60 |
ms ms | 60 |
type ii | 60 |
odds ratio | 60 |
influenza vaccination | 60 |
regression model | 60 |
day post | 60 |
oxidative stress | 59 |
relapse mortality | 59 |
frozen plasma | 59 |
cardiac output | 59 |
cell proliferation | 59 |
predictive value | 59 |
cytopathic effect | 59 |
data set | 59 |
severe cases | 59 |
risk group | 58 |
pcr assay | 58 |
cpg sites | 58 |
donor chimerism | 58 |
cell therapy | 58 |
bacterial infection | 58 |
innate immunity | 58 |
sampling volume | 58 |
also observed | 58 |
supportive care | 58 |
may cause | 58 |
influenza surveillance | 57 |
secondary metabolites | 57 |
platelet engraftment | 57 |
hematological malignancies | 57 |
cell lymphoma | 57 |
east respiratory | 57 |
blood donor | 57 |
patients developed | 57 |
age years | 57 |
inclusion criteria | 57 |
infectious complications | 57 |
retrospective cohort | 57 |
phase i | 57 |
months post | 57 |
severe combined | 56 |
hospital discharge | 56 |
transcription factors | 56 |
elderly patients | 56 |
cell source | 56 |
current study | 56 |
virus titers | 56 |
hcv infection | 56 |
clinical data | 56 |
blood gas | 56 |
first time | 56 |
unrelated donors | 55 |
higher risk | 55 |
cell cultures | 55 |
viruses isolated | 55 |
first days | 55 |
cell dose | 55 |
general population | 55 |
disease progression | 55 |
molecular docking | 54 |
acute lymphoblastic | 54 |
risk patients | 54 |
significant decrease | 54 |
blood donation | 54 |
clinical characteristics | 54 |
vaccine development | 54 |
viral shedding | 54 |
cystic fibrosis | 54 |
rhce ce | 54 |
cd ra | 54 |
renal function | 54 |
data collection | 54 |
clinical specimens | 54 |
retrospectively analyzed | 54 |
health literacy | 54 |
univariate analysis | 54 |
spinal cord | 54 |
social distancing | 54 |
controlled trial | 54 |
ag cur | 54 |
antibody screen | 54 |
human serum | 54 |
mass spectrometric | 54 |
clinically significant | 53 |
hazard function | 53 |
background adaptation | 53 |
icu mortality | 53 |
poor prognosis | 53 |
arterial pressure | 53 |
assisted laser | 53 |
first hours | 53 |
mhc class | 53 |
zika virus | 53 |
host response | 53 |
results indicate | 53 |
homo sapiens | 53 |
acute graft | 52 |
traumatic brain | 52 |
left ventricular | 52 |
copies ml | 52 |
results showed | 52 |
nk cell | 52 |
fresh frozen | 52 |
analysis revealed | 52 |
mean arterial | 52 |
authors declare | 52 |
clinical features | 52 |
metabolic acidosis | 52 |
significantly reduced | 52 |
rbc transfusion | 51 |
cancer patients | 51 |
combined immunodeficiency | 51 |
month period | 51 |
functional ingredients | 51 |
influenza vaccines | 51 |
vaccine candidates | 51 |
antibody titers | 51 |
antiviral drugs | 51 |
human proteome | 51 |
prognostic value | 51 |
case growth | 51 |
increased mortality | 50 |
fever virus | 50 |
host cells | 50 |
ml min | 50 |
whenever possible | 50 |
pathogenic avian | 50 |
pleural effusion | 50 |
higher levels | 50 |
ic values | 50 |
hospital cardiac | 50 |
urine output | 50 |
computed tomography | 50 |
blood glucose | 50 |
may result | 50 |
ethics committee | 50 |
first reported | 50 |
analyzed using | 50 |
white blood | 50 |
receptor binding | 50 |
early diagnosis | 50 |
year os | 49 |
binding protein | 49 |
significant reduction | 49 |
ventilated patients | 49 |
inflammatory cytokines | 49 |
medical records | 49 |
prospective observational | 49 |
body mass | 49 |
serum samples | 49 |
sialic acid | 49 |
respiratory illness | 48 |
tof tof | 48 |
reproduction number | 48 |
respiratory symptoms | 48 |
drinking water | 48 |
taken together | 48 |
also showed | 48 |
respiratory rate | 48 |
hulless barley | 48 |
analysis using | 48 |
new york | 48 |
animal models | 48 |
well tolerated | 48 |
porcine epidemic | 48 |
young children | 48 |
total body | 48 |
dose chemotherapy | 48 |
virus ns | 48 |
intrinsic disorder | 48 |
independently associated | 47 |
data analysis | 47 |
induce emesis | 47 |
tract infection | 47 |
data suggest | 47 |
high quality | 47 |
water supply | 47 |
patient characteristics | 47 |
nitric oxide | 47 |
magnetic resonance | 47 |
year overall | 47 |
red cells | 47 |
test results | 47 |
clinical symptoms | 47 |
patients underwent | 47 |
small number | 47 |
many cases | 47 |
lymphoblastic leukemia | 47 |
calculated using | 47 |
liquid chromatography | 47 |
respiratory disease | 47 |
neutrophil engraftment | 47 |
mask mandate | 47 |
may provide | 47 |
family members | 47 |
rights reserved | 47 |
expression levels | 46 |
pregnant women | 46 |
low levels | 46 |
oxygen saturation | 46 |
hemorrhagic fever | 46 |
massive transfusion | 46 |
patients showed | 46 |
protein expression | 46 |
median number | 46 |
sequence alignment | 46 |
sampling tube | 46 |
rna polymerase | 46 |
red cross | 46 |
sore throat | 46 |
serum albumin | 46 |
center background | 46 |
different types | 46 |
liver disease | 46 |
cells kg | 46 |
previously identified | 46 |
also known | 45 |
exact test | 45 |
per patient | 45 |
direct contact | 45 |
aplastic anemia | 45 |
gene therapy | 45 |
trauma patients | 45 |
hcv replication | 45 |
artery disease | 45 |
respiratory viral | 45 |
measured using | 45 |
less likely | 45 |
active disease | 45 |
control measures | 45 |
blood cultures | 45 |
icu discharge | 45 |
rhinovirus infection | 45 |
cell cycle | 45 |
patients requiring | 45 |
cardiovascular disease | 45 |
cell viability | 45 |
cell types | 45 |
may require | 45 |
mg ml | 44 |
umbilical cord | 44 |
may contribute | 44 |
hla class | 44 |
epidemic diarrhea | 44 |
live attenuated | 44 |
perform orogastric | 44 |
cell wall | 44 |
results show | 44 |
results obtained | 44 |
year old | 44 |
time rt | 44 |
recent studies | 44 |
physical activity | 44 |
sequence similarity | 44 |
cho cell | 44 |
hemolytic anemia | 44 |
healthy donors | 44 |
male reproductive | 44 |
myocardial infarction | 44 |
cause mortality | 44 |
sickle cell | 44 |
hematologic malignancies | 44 |
abo rh | 43 |
healthcare workers | 43 |
evaluated using | 43 |
protein production | 43 |
lung disease | 43 |
respiratory depression | 43 |
protein synthesis | 43 |
molecular weight | 43 |
cells ml | 43 |
candidate genes | 43 |
tyrosine kinase | 43 |
high throughput | 43 |
chest pain | 43 |
viral entry | 43 |
supplementary tables | 43 |
study shows | 43 |
baseline characteristics | 43 |
survival rate | 43 |
first wave | 43 |
aml patients | 43 |
ae log | 43 |
study population | 43 |
phase ii | 43 |
hours post | 43 |
pts received | 43 |
dendritic cells | 42 |
blood type | 42 |
virus isolation | 42 |
ct value | 42 |
acute lung | 42 |
reproductive tissue | 42 |
blood supply | 42 |
container slot | 42 |
blood donations | 42 |
clinical course | 42 |
blood centers | 42 |
natural products | 42 |
administer intravenous | 42 |
shock patients | 42 |
job demands | 42 |
sampling flow | 42 |
mycophenolate mofetil | 42 |
data collected | 42 |
streptococcal pharyngitis | 42 |
body temperature | 42 |
multiple organ | 42 |
patients aged | 42 |
viral loads | 42 |
study group | 42 |
cause severe | 42 |
host immune | 42 |
like protease | 42 |
study included | 42 |
pulmonary disease | 42 |
rsv infection | 42 |
ii score | 42 |
signaling pathway | 42 |
specific genes | 42 |
primary immunodeficiency | 42 |
antibody responses | 42 |
reference standard | 42 |
naturally occurring | 42 |
year period | 41 |
event day | 41 |
regulatory network | 41 |
plasma membrane | 41 |
entrepreneurial capabilities | 41 |
aged years | 41 |
significantly decreased | 41 |
samples collected | 41 |
grade i | 41 |
ang ii | 41 |
less common | 41 |
two cases | 41 |
respiratory virus | 41 |
preventive measures | 41 |
kidney transplant | 41 |
immune reconstitution | 41 |
severe respiratory | 41 |
genes involved | 41 |
differential diagnosis | 41 |
previous study | 41 |
crystalloid fluids | 41 |
early detection | 41 |
protein sequence | 41 |
ct values | 41 |
wound healing | 41 |
distemper virus | 41 |
pandemic virus | 41 |
fluid balance | 41 |
ha gene | 41 |
seven patients | 41 |
poor outcome | 41 |
higher mortality | 41 |
low dose | 41 |
febrile neutropenia | 41 |
pathogen reduction | 41 |
described previously | 41 |
cell responses | 41 |
two weeks | 41 |
data sets | 41 |
protease inhibitor | 41 |
endoplasmic reticulum | 41 |
confidence intervals | 41 |
virus strains | 41 |
patient safety | 41 |
meo ma | 40 |
available data | 40 |
atrial fibrillation | 40 |
children aged | 40 |
patients transplanted | 40 |
fatty acid | 40 |
medical record | 40 |
vaccine strain | 40 |
clinical samples | 40 |
six patients | 40 |
organ transplant | 40 |
mast cell | 40 |
converting enzyme | 40 |
three different | 40 |
reverse transcriptase | 40 |
binding site | 40 |
matched related | 40 |
bacterial pneumonia | 40 |
patients presented | 40 |
united kingdom | 40 |
rna replication | 40 |
roc curve | 40 |
north america | 40 |
basic reproduction | 40 |
also identified | 40 |
donor type | 40 |
immunodeficiency virus | 40 |
hodgkin lymphoma | 40 |
fold increase | 40 |
general anesthesia | 40 |
platelet counts | 40 |
high doses | 40 |
cell epitopes | 40 |
small intestine | 39 |
three viruses | 39 |
waterborne illness | 39 |
transfusion reaction | 39 |
significant impact | 39 |
older adults | 39 |
underlying cause | 39 |
first case | 39 |
without permission | 39 |
barley grains | 39 |
phenolic compounds | 39 |
common cause | 39 |
key role | 39 |
success rate | 39 |
median duration | 39 |
false positive | 39 |
venous catheter | 39 |
case study | 39 |
controlled trials | 39 |
kg hour | 39 |
fluid therapy | 39 |
transmission rate | 39 |
school closures | 39 |
eight patients | 39 |
opioid receptors | 39 |
reuse allowed | 39 |
tidal volume | 39 |
sos vod | 39 |
allowed without | 39 |
based university | 39 |
recombinant protein | 39 |
readily available | 39 |
human immunodeficiency | 39 |
based approach | 38 |
spectrum antibiotics | 38 |
determined using | 38 |
gene segments | 38 |
life cycle | 38 |
lever presses | 38 |
sibling donor | 38 |
spike protein | 38 |
pilot study | 38 |
published data | 38 |
hsct recipients | 38 |
similar results | 38 |
study showed | 38 |
kidney disease | 38 |
acei arb | 38 |
made available | 38 |
transcription factor | 38 |
progressive disease | 38 |
matched sibling | 38 |
patients may | 38 |
combination therapy | 38 |
recent study | 38 |
patient died | 38 |
case report | 38 |
patients included | 38 |
rung orthopair | 38 |
applied biosystems | 38 |
diarrhea virus | 38 |
target genes | 38 |
median cd | 38 |
table ii | 37 |
myelodysplastic syndrome | 37 |
linear regression | 37 |
like illness | 37 |
patient received | 37 |
genome sequences | 37 |
seq data | 37 |
diagnostic tests | 37 |
phylogenetic tree | 37 |
data points | 37 |
kg minute | 37 |
cancer cell | 37 |
food security | 37 |
plasma levels | 37 |
homology modelling | 37 |
least two | 37 |
expressed genes | 37 |
statin group | 37 |
stranded rna | 37 |
collected data | 37 |
higher incidence | 37 |
respiratory infection | 37 |
much higher | 37 |
consecutive days | 37 |
correlation coefficient | 37 |
galnac utilization | 37 |
market matching | 37 |
antiviral agents | 37 |
assessed using | 37 |
sialic acids | 36 |
bronchoalveolar lavage | 36 |
pdb id | 36 |
hazard ratio | 36 |
nasal swabs | 36 |
states department | 36 |
mm patients | 36 |
study demonstrated | 36 |
differential expression | 36 |
glycosylation sites | 36 |
hla matched | 36 |
concentrating hormone | 36 |
fold change | 36 |
streptococcus suis | 36 |
haploidentical donor | 36 |
biological evaluation | 36 |
fold higher | 36 |
case series | 36 |
high prevalence | 36 |
complete blood | 36 |
neutralizing antibodies | 36 |
apheresis platelets | 36 |
hospitalized patients | 36 |
pseudomonas aeruginosa | 36 |
virus antigen | 36 |
herpes simplex | 36 |
significantly improved | 36 |
patient outcomes | 36 |
sequence identity | 36 |
serine protease | 36 |
three times | 36 |
tertiary care | 36 |
particle counter | 36 |
signal transduction | 36 |
cell activation | 36 |
mesenchymal stem | 36 |
blood services | 36 |
first day | 36 |
kcal mol | 36 |
cov cl | 36 |
qsar model | 35 |
see supplementary | 35 |
dynamic capabilities | 35 |
cysteine proteases | 35 |
antiviral treatment | 35 |
viral particles | 35 |
face masks | 35 |
vaccination strategies | 35 |
chinese hamster | 35 |
high school | 35 |
clinical studies | 35 |
mass index | 35 |
cardiovascular diseases | 35 |
several studies | 35 |
sequence analysis | 35 |
patient samples | 35 |
based conditioning | 35 |
early stage | 35 |
treatment options | 35 |
prospective cohort | 35 |
patient population | 35 |
study suggests | 35 |
relapse rate | 35 |
sgh symptoms | 35 |
single cell | 35 |
cytokine production | 35 |
graphical representations | 35 |
secondary outcomes | 35 |
clinical significance | 35 |
broad spectrum | 35 |
obese patients | 35 |
hospital admission | 35 |
ic value | 35 |
ejection fraction | 35 |
acid residues | 35 |
natural killer | 35 |
oxygen delivery | 35 |
insecure households | 35 |
galn galnac | 35 |
genome assembly | 35 |
drug discovery | 34 |
minimum sampling | 34 |
specific antibodies | 34 |
nucleotide sequences | 34 |
also tested | 34 |
disseminated intravascular | 34 |
publicly available | 34 |
slightly lower | 34 |
gel electrophoresis | 34 |
hemophagocytic lymphohistiocytosis | 34 |
risk assessment | 34 |
positive correlation | 34 |
nine patients | 34 |
cell depletion | 34 |
electronic medical | 34 |
baseline hazard | 34 |
cell disease | 34 |
cl pro | 34 |
blood component | 34 |
high level | 34 |
urinary tract | 34 |
future studies | 34 |
reported case | 34 |
autologous hsct | 34 |
better understanding | 34 |
north american | 34 |
dependent variable | 34 |
iu ml | 34 |
density lipoprotein | 34 |
cleavage site | 34 |
type diabetes | 34 |
contact tracing | 34 |
nd allo | 34 |
underlying disease | 34 |
intravascular coagulation | 34 |
nucleotide sequence | 34 |
cell depleted | 34 |
tested positive | 34 |
plasma exchange | 34 |
overall mortality | 34 |
four different | 34 |
bispecific antibodies | 34 |
pro inhibitors | 34 |
body irradiation | 34 |
ionization mass | 34 |
case definition | 33 |
process development | 33 |
complete response | 33 |
gold standard | 33 |
time reverse | 33 |
endotracheal tube | 33 |
opioid receptor | 33 |
ms analysis | 33 |
emergency care | 33 |
table i | 33 |
structural characterization | 33 |
relatively low | 33 |
also associated | 33 |
fast set | 33 |
blood mononuclear | 33 |
sterile saline | 33 |
blood count | 33 |
next generation | 33 |
perceived severity | 33 |
high incidence | 33 |
high titer | 33 |
multiple sequence | 33 |
disease relapse | 33 |
cd deficiency | 33 |
whole grains | 33 |
lung transplant | 33 |
binding residues | 33 |
hydrogen bond | 33 |
per week | 33 |
platelet recovery | 33 |
hamster ovary | 33 |
severe sepsis | 33 |
survival rates | 33 |
intravenous crystalloid | 33 |
antiviral effect | 32 |
post transplant | 32 |
airway obstruction | 32 |
neural networks | 32 |
like receptor | 32 |
based studies | 32 |
last years | 32 |
intravenous fluid | 32 |
acute phase | 32 |
tumor cells | 32 |
healthcare personnel | 32 |
active lever | 32 |
placebo group | 32 |
biological activity | 32 |
acid sequence | 32 |
old female | 32 |
quality improvement | 32 |
staphylococcus aureus | 32 |
wild type | 32 |
years ago | 32 |
infected individuals | 32 |
reported cases | 32 |
saline solution | 32 |
related complications | 32 |
human proteins | 32 |
patients infected | 32 |
negative ion | 32 |
total rna | 32 |
older patients | 32 |
relapsed refractory | 32 |
viral pathogens | 32 |
cysteine cathepsins | 32 |
patient blood | 32 |
human cathepsin | 32 |
standard errors | 32 |
corona virus | 32 |
hemorrhagic cystitis | 32 |
randomly selected | 32 |
service users | 32 |
clinical use | 32 |
demographic data | 32 |
solid phase | 32 |
human health | 32 |
effective treatment | 32 |
interquartile range | 32 |
allogeneic sct | 32 |
structural analysis | 32 |
hydrogen bonds | 32 |
ten patients | 32 |
mask usage | 32 |
confirmed cases | 32 |
patients achieved | 32 |
female workers | 32 |
chicken eggs | 32 |
stimulating factor | 31 |
receiver operating | 31 |
differential diagnoses | 31 |
study also | 31 |
recurrent infections | 31 |
reactive oxygen | 31 |
surface area | 31 |
fatty acids | 31 |
tumor growth | 31 |
findings suggest | 31 |
significantly regulated | 31 |
simulation model | 31 |
iv acute | 31 |
chronic pain | 31 |
face mask | 31 |
may include | 31 |
study aimed | 31 |
antibody production | 31 |
significant improvement | 31 |
fluid resuscitation | 31 |
i ifn | 31 |
barr virus | 31 |
coronary heart | 31 |
first two | 31 |
ion mode | 31 |
treatment consists | 31 |
water deficit | 31 |
immune cells | 31 |
air pollution | 31 |
healthy volunteers | 31 |
missing data | 31 |
good performance | 31 |
rna virus | 31 |
spiral drawings | 31 |
remains unclear | 31 |
ill persons | 31 |
necrosis factor | 31 |
clinical presentation | 31 |
exclusion criteria | 31 |
serum levels | 31 |
three months | 31 |
research institute | 31 |
plasma samples | 31 |
data indicate | 31 |
done using | 31 |
based design | 31 |
fusion proteins | 31 |
factor viii | 31 |
genome sequence | 31 |
related donor | 30 |
inactivated influenza | 30 |
may reduce | 30 |
resistant viruses | 30 |
protective effect | 30 |
hcv rna | 30 |
southern china | 30 |
intravenous catheter | 30 |
showed significant | 30 |
viral pneumonia | 30 |
statistically significantly | 30 |
protein interaction | 30 |
high rate | 30 |
tandem mass | 30 |
single dose | 30 |
mammalian cells | 30 |
also shown | 30 |
radiation exposure | 30 |
critical role | 30 |
membrane oxygenation | 30 |
medical management | 30 |
nucleic acids | 30 |
drug targets | 30 |
drug development | 30 |
human igg | 30 |
partial response | 30 |
viral protein | 30 |
treatment option | 30 |
linked glycans | 30 |
perceived susceptibility | 30 |
patient developed | 30 |
mortality risk | 30 |
three groups | 30 |
cancellation probability | 30 |
regression models | 30 |
high yield | 30 |
donor lymphocyte | 30 |
dependent manner | 30 |
study conducted | 30 |
emergency medicine | 30 |
mixed chimerism | 30 |
study participants | 30 |
conducted using | 30 |
clinical outcome | 30 |
drug resistance | 30 |
chronic kidney | 30 |
star scientist | 30 |
better understand | 30 |
clinically relevant | 30 |
every hours | 30 |
viable cell | 30 |
solid organ | 30 |
soft tissue | 30 |
acute renal | 30 |
thrombin generation | 30 |
docking studies | 30 |
genome sequencing | 30 |
limited number | 29 |
mrna expression | 29 |
days prior | 29 |
significant correlation | 29 |
local anesthetic | 29 |
genomic dna | 29 |
adjuvanted vaccine | 29 |
square test | 29 |
medrxiv preprint | 29 |
autologous hematopoietic | 29 |
primary endpoint | 29 |
pcr assays | 29 |
progenitor cells | 29 |
table presents | 29 |
cancer therapy | 29 |
took place | 29 |
prophylaxis consisted | 29 |
target cells | 29 |
library preparation | 29 |
aldrich syndrome | 29 |
invasive mechanical | 29 |
marrow transplant | 29 |
transfusion vol | 29 |
immune checkpoint | 29 |
vs days | 29 |
national institute | 29 |
high frequency | 29 |
median day | 29 |
enzyme activity | 29 |
aggregation operators | 29 |
international license | 29 |
may become | 29 |
genetic diversity | 29 |
sodium bicarbonate | 29 |
well plates | 29 |
retrospective observational | 29 |
significantly better | 29 |
developing countries | 29 |
recombinant human | 29 |
vp vp | 29 |
specific cd | 29 |
container shipping | 29 |
viral respiratory | 29 |
generation sequencing | 29 |
surgical patients | 29 |
study aims | 29 |
pdm virus | 29 |
click chemistry | 29 |
final concentration | 29 |
residues tof | 29 |
tissue culture | 29 |
reproductive health | 29 |
normal levels | 29 |
may play | 29 |
phylogenetic trees | 29 |
west nile | 29 |
gvhd grade | 29 |
also performed | 29 |
make sure | 29 |
dipole moment | 29 |
data regarding | 29 |
western blot | 29 |
main cause | 29 |
antiviral drug | 29 |
oxygen species | 29 |
within months | 29 |
three days | 29 |
side chain | 29 |
sequence data | 29 |
slot bookings | 28 |
tested using | 28 |
data obtained | 28 |
information system | 28 |
hiv infection | 28 |
acid changes | 28 |
secondary bacterial | 28 |
household food | 28 |
ct scan | 28 |
blood management | 28 |
acid sequences | 28 |
protein kinase | 28 |
extracorporeal membrane | 28 |
radiation therapy | 28 |
water treatment | 28 |
transplant cyclophosphamide | 28 |
phylogenetic analyses | 28 |
tabular data | 28 |
identical sibling | 28 |
institutional review | 28 |
different cell | 28 |
cysteine protease | 28 |
cardiogenic shock | 28 |
antioxidant activity | 28 |
one case | 28 |
autoimmune diseases | 28 |
job resources | 28 |
negative control | 28 |
embryonated chicken | 28 |
blood banks | 28 |
preliminary results | 28 |
tissue samples | 28 |
serum creatinine | 28 |
full donor | 28 |
cardiovascular risk | 28 |
primary care | 28 |
specific primers | 28 |
healthy adults | 28 |
influenza strains | 28 |
many patients | 28 |
patients diagnosed | 28 |
hydrogen bonding | 28 |
haematopoietic stem | 28 |
first line | 28 |
machine learning | 28 |
gene set | 28 |
drug administration | 28 |
cerebral edema | 28 |
major cause | 28 |
upper airway | 28 |
bariatric surgery | 28 |
failure assessment | 28 |
tumor necrosis | 28 |
mathematical model | 28 |
patients presenting | 28 |
biosensor surface | 28 |
may affect | 28 |
results demonstrate | 28 |
infections caused | 28 |
literature review | 28 |
expression data | 28 |
etiologic agent | 28 |
otitis media | 28 |
cell function | 28 |
also significantly | 28 |
blood culture | 28 |
endothelial cell | 28 |
lung tissue | 28 |
regression results | 28 |
severe infections | 28 |
transfection efficiency | 28 |
platelet concentrates | 28 |
viral proteomes | 28 |
neutrophil count | 28 |
mucous membranes | 28 |
improved survival | 28 |
hemolytic transfusion | 27 |
th day | 27 |
much less | 27 |
sequential organ | 27 |
risk stratification | 27 |
global health | 27 |
natural history | 27 |
genes identified | 27 |
cns disorders | 27 |
highly conserved | 27 |
pao fio | 27 |
influenza season | 27 |
reaction mixture | 27 |
see appendix | 27 |
may reveal | 27 |
transfusion services | 27 |
small sample | 27 |
antifungal prophylaxis | 27 |
randomized clinical | 27 |
high affinity | 27 |
health status | 27 |
median days | 27 |
insert table | 27 |
food access | 27 |
factor receptor | 27 |
active shooter | 27 |
chronic graft | 27 |
test performance | 27 |
may represent | 27 |
female patients | 27 |
emerging infectious | 27 |
two years | 27 |
case reports | 27 |
sample collection | 27 |
platelet transfusion | 27 |
comparative analysis | 27 |
group compared | 27 |
per month | 27 |
adhesion molecule | 27 |
convalescent plasma | 27 |
laboratory data | 27 |
homeland security | 27 |
likely due | 27 |
neuraminidase inhibitors | 27 |
nucleocapsid protein | 27 |
relapse incidence | 27 |
hormonal status | 27 |
pulse oximetry | 27 |
consistently food | 27 |
undergoing hsct | 27 |
term survival | 27 |
line therapy | 27 |
urinary catheter | 27 |
epidemic curve | 27 |
extracorporeal photopheresis | 27 |
chronic granulomatous | 27 |
school closure | 27 |
much lower | 27 |
fusion protein | 27 |
diagnostic accuracy | 27 |
year survival | 27 |
new zealand | 27 |
medical care | 27 |
health system | 27 |
high number | 27 |
copy number | 27 |
partial remission | 27 |
crafting behaviors | 27 |
vaccine production | 27 |
reference laboratory | 27 |
hospital length | 27 |
negative bacteria | 27 |
stroke volume | 27 |
leading cause | 27 |
virus type | 27 |
tumour specific | 27 |
intracranial pressure | 27 |
liner shipping | 27 |
underwent allogeneic | 27 |
renal disease | 27 |
continuous variables | 26 |
based approaches | 26 |
brainstem dysfunction | 26 |
also assessed | 26 |
mrna splicing | 26 |
one month | 26 |
human cells | 26 |
drug interactions | 26 |
fda approved | 26 |
expression level | 26 |
future research | 26 |
virus infected | 26 |
resistant starch | 26 |
wild carnivores | 26 |
atg group | 26 |
average age | 26 |
isokinetic sampling | 26 |
one hundred | 26 |
respiratory diseases | 26 |
maternal plasma | 26 |
proteins involved | 26 |
vaccine candidate | 26 |
frequently used | 26 |
volume reduction | 26 |
bacterial contamination | 26 |
particle size | 26 |
barley grass | 26 |
common causes | 26 |
small molecules | 26 |
method using | 26 |
alignment methods | 26 |
nonstructural protein | 26 |
may appear | 26 |
increasing number | 26 |
lower risk | 26 |
culture medium | 26 |
adenovirus type | 26 |
cardiovascular fibrosis | 26 |
many countries | 26 |
cell counts | 26 |
surface plasmon | 26 |
loss rate | 26 |
inflammatory cytokine | 26 |
disease regulated | 26 |
recombinant proteins | 26 |
immunosuppressive therapy | 26 |
healthcare settings | 26 |
inhalational anthrax | 26 |
higher number | 26 |
occlusive disease | 26 |
law enforcement | 26 |
patients experienced | 26 |
cell adhesion | 26 |
similarity measure | 26 |
virtual screening | 26 |
viral genome | 26 |
myeloma patients | 26 |
differ significantly | 26 |
statistical analyses | 26 |
using standard | 26 |
year mortality | 26 |
within minutes | 26 |
may present | 26 |
respiratory system | 26 |
significant risk | 26 |
vascular endothelial | 26 |
knockout mice | 26 |
chloroquine derivatives | 26 |
average number | 26 |
showed high | 26 |
may increase | 26 |
functional characterization | 26 |
clinical syndromes | 26 |
cardiac dysrhythmias | 26 |
broad range | 26 |
previous reports | 26 |
young adults | 26 |
investigate whether | 26 |
ae lg | 26 |
experimental data | 26 |
emergency room | 26 |
transplant related | 26 |
different time | 26 |
emergency medical | 26 |
inflammatory markers | 25 |
virus isolates | 25 |
acute coronary | 25 |
thoracic radiographs | 25 |
american red | 25 |
tight junction | 25 |
molecular structure | 25 |
kg body | 25 |
congenital heart | 25 |
angiotensin ii | 25 |
protein interactions | 25 |
recent advances | 25 |
protective immunity | 25 |
iv cri | 25 |
negative correlation | 25 |
new method | 25 |
may produce | 25 |
written informed | 25 |
additional information | 25 |
per unit | 25 |
media literacy | 25 |
side effect | 25 |
comorbidity index | 25 |
months later | 25 |
laboratory testing | 25 |
several days | 25 |
expression patterns | 25 |
coffee intake | 25 |
similarity measures | 25 |
plasmodium falciparum | 25 |
abdominal surgery | 25 |
respiratory secretions | 25 |
advisory committee | 25 |
bioactive compounds | 25 |
susceptibility testing | 25 |
transgenic mice | 25 |
mammalian cell | 25 |
vaccine strains | 25 |
nsp proteins | 25 |
related genes | 25 |
antibody identification | 25 |
chest radiograph | 25 |
died due | 25 |
broccoli sprout | 25 |
significant effect | 25 |
currently available | 25 |
genes encoding | 25 |
protein data | 25 |
regulated genes | 25 |
first step | 25 |
functional status | 25 |
fluid administration | 25 |
anterior chamber | 25 |
significantly greater | 25 |
first months | 25 |
term follow | 25 |
aspiration pneumonia | 25 |
blood service | 25 |
cell clones | 25 |
see chapter | 25 |
case fatality | 25 |
information hiding | 25 |
posted september | 25 |
last follow | 25 |
analysed using | 25 |
single centre | 25 |
antibiotic treatment | 25 |
patients engrafted | 25 |
cox model | 25 |
expression profiles | 25 |
chest ct | 25 |
first dose | 25 |
flow cytometric | 25 |
time interval | 25 |
pandemic vaccine | 25 |
granulomatous disease | 25 |
electrolyte abnormalities | 25 |
units transfused | 25 |
environmental factors | 25 |
well known | 25 |
also occur | 25 |
founding team | 25 |
membrane protein | 25 |
studies using | 25 |
large volume | 25 |
national institutes | 25 |
care medicine | 25 |
close contact | 25 |
will need | 25 |
virus concentration | 25 |
also reported | 25 |
antiviral therapy | 25 |
possible role | 25 |
one week | 25 |
relative risk | 25 |
past years | 25 |
toxic effects | 25 |
center study | 25 |
booking time | 25 |
chart review | 25 |
tissue damage | 25 |
factor model | 25 |
binding kinetics | 24 |
observational studies | 24 |
low risk | 24 |
prospective studies | 24 |
older children | 24 |
web server | 24 |
two months | 24 |
haploidentical hsct | 24 |
genetic analysis | 24 |
antigenic sites | 24 |
hypovolemic shock | 24 |
nile virus | 24 |
cell development | 24 |
human coronavirus | 24 |
brain barrier | 24 |
reverse genetics | 24 |
group i | 24 |
human cell | 24 |
congo hemorrhagic | 24 |
symptom onset | 24 |
novel human | 24 |
salvage therapy | 24 |
positive control | 24 |
older age | 24 |
infectious agents | 24 |
pedv infection | 24 |
inflammatory responses | 24 |
like viruses | 24 |
liver cancer | 24 |
shipping service | 24 |
towards cathepsin | 24 |
host defense | 24 |
growth factors | 24 |
neural network | 24 |
dna sequence | 24 |
saudi arabia | 24 |
review board | 24 |
random network | 24 |
term outcome | 24 |
multivariable analysis | 24 |
human macrophages | 24 |
care workers | 24 |
vital signs | 24 |
signs include | 24 |
viral culture | 24 |
pandemic potential | 24 |
malignant disease | 24 |
may indicate | 24 |
incidence rate | 24 |
disease risk | 24 |
blood sample | 24 |
complement activation | 24 |
potential therapeutic | 24 |
clinical information | 24 |
rbc transfusions | 24 |
relatively small | 24 |
invasive fungal | 24 |
chimeric antigen | 24 |
assistance programs | 24 |
saccharomyces cerevisiae | 24 |
genes associated | 24 |
transplant patients | 24 |
donor center | 24 |
systemic inflammatory | 24 |
nsp protein | 24 |
will also | 24 |
neurological outcome | 24 |
water source | 24 |
ethylene glycol | 24 |
residual disease | 24 |
quantitative pcr | 24 |
bact alert | 24 |
large scale | 24 |
strongly associated | 24 |
data quality | 24 |
ebola virus | 24 |
birth weight | 24 |
ebv reactivation | 24 |
igg levels | 24 |
free energy | 24 |
medical history | 24 |
human respiratory | 24 |
two main | 24 |
hand washing | 24 |
enteric viruses | 24 |
agar protein | 24 |
old male | 24 |
mdck pf | 24 |
median os | 24 |
na gene | 24 |
binding domain | 24 |
risk groups | 24 |
icu length | 24 |
heavy chain | 24 |
south africa | 24 |
see tables | 24 |
began shooting | 24 |
high sensitivity | 24 |
simplex virus | 24 |
signs associated | 24 |
venom proteins | 24 |
active compounds | 24 |
hybrid nps | 23 |
germ cell | 23 |
negative predictive | 23 |
mcg kg | 23 |
coiled coil | 23 |
regional blood | 23 |
statin treatment | 23 |
therapy may | 23 |
sample period | 23 |
origin influenza | 23 |
post hsct | 23 |
negative results | 23 |
geometric mean | 23 |
will help | 23 |
binding affinities | 23 |
viral infectivity | 23 |
safety profile | 23 |
na genes | 23 |
bovine serum | 23 |
medical therapy | 23 |
mortality among | 23 |
newly diagnosed | 23 |
health authorities | 23 |
pesq scores | 23 |
benchmark dataset | 23 |
allogeneic transplantation | 23 |
cd expression | 23 |
identify patients | 23 |
adverse reactions | 23 |
induction therapy | 23 |
target gene | 23 |
also may | 23 |
accuracy assessment | 23 |
cell index | 23 |
times higher | 23 |
remaining patients | 23 |
patients suffering | 23 |
activity relationship | 23 |
assess whether | 23 |
systemic inflammation | 23 |
fractal dimensions | 23 |
virus transmission | 23 |
enrolled patients | 23 |
passive immunotherapy | 23 |
dependent rna | 23 |
immunocompromised patients | 23 |
cough reflex | 23 |
fc fusion | 23 |
head trauma | 23 |
infected persons | 23 |
per kg | 23 |
patients hospitalized | 23 |
posted october | 23 |
healthy subjects | 23 |
model parameters | 23 |
mdck cell | 23 |
days later | 23 |
severity score | 23 |
extracellular matrix | 23 |
rabies virus | 23 |
cereal intake | 23 |
cells expressing | 23 |
organ damage | 23 |
general self | 23 |
lung ultrasound | 23 |
generated using | 23 |
th cells | 23 |
clinical stage | 23 |
immune function | 23 |
salivary gland | 23 |
whole genome | 23 |
spectral representation | 23 |
th percentile | 23 |
venous blood | 23 |
cox regression | 23 |
oseltamivir resistance | 23 |
cell type | 23 |
early stages | 23 |
plasmon resonance | 23 |
igg subclass | 23 |
plasma concentrations | 23 |
transplanted patients | 23 |
lactic acid | 23 |
severe chronic | 23 |
infectious virus | 23 |
cell response | 23 |
wbc count | 23 |
encephalitis virus | 23 |
terminal region | 23 |
higher education | 23 |
orthopair uncertain | 23 |
model obtained | 23 |
dengue virus | 23 |
sepsis patients | 23 |
particle concentration | 23 |
light chain | 23 |
attack rate | 23 |
urinary bladder | 23 |
mainly due | 23 |
highly significant | 23 |
two types | 23 |
emergency management | 23 |
severe illness | 23 |
beneficial effect | 23 |
higher rate | 23 |
i ii | 23 |
rapid detection | 23 |
among different | 23 |
retrospective review | 23 |
virus production | 23 |
weekly case | 23 |
maintain hydration | 23 |
often used | 23 |
term care | 23 |
chronic disease | 23 |
detection limit | 23 |
center experience | 23 |
new cases | 23 |
considered statistically | 23 |
vascular access | 23 |
human infection | 23 |
similarity dissimilarity | 23 |
nasal discharge | 23 |
kg min | 23 |
patients required | 23 |
well plate | 23 |
buffy coat | 23 |
renal perfusion | 23 |
patients years | 23 |
study revealed | 23 |
last decade | 23 |
food assistance | 23 |
sequence reads | 23 |
treated patients | 23 |
primary immunodeficiencies | 22 |
infused cd | 22 |
line treatment | 22 |
table iv | 22 |
filter media | 22 |
origin country | 22 |
coronary angiography | 22 |
expression profile | 22 |
secondary cases | 22 |
group patients | 22 |
mouse models | 22 |
significant association | 22 |
high degree | 22 |
virus vaccine | 22 |
increased expression | 22 |
antibody titer | 22 |
table iii | 22 |
reproductive number | 22 |
cell carcinoma | 22 |
received myeloablative | 22 |
negative effect | 22 |
data suggests | 22 |
mayo clinic | 22 |
classification performance | 22 |
second dose | 22 |
copy numbers | 22 |
group received | 22 |
mean duration | 22 |
high morbidity | 22 |
utilization pathway | 22 |
human transmission | 22 |
lymph node | 22 |
infected mice | 22 |
symptomatic cases | 22 |
care patients | 22 |
pathogen inactivation | 22 |
aseptically scrub | 22 |
nasal washes | 22 |
regimen consisted | 22 |
many studies | 22 |
effi cacy | 22 |
structural determination | 22 |
per ml | 22 |
nutritional support | 22 |
recently reported | 22 |
one unit | 22 |
ventricular dysrhythmias | 22 |
congestive heart | 22 |
graft rejection | 22 |
different levels | 22 |
adaptive immunity | 22 |
first week | 22 |
care facilities | 22 |
molecular dynamics | 22 |
cerebrospinal fluid | 22 |
signal peptide | 22 |
go terms | 22 |
based vaccines | 22 |
sars patients | 22 |
speech codec | 22 |
viral titers | 22 |
hydroxyl groups | 22 |
developed severe | 22 |
two days | 22 |
bispecific antibody | 22 |
several times | 22 |
transfusion practice | 22 |
human epididymis | 22 |
parenteral nutrition | 22 |
expression analysis | 22 |
molecular basis | 22 |
dissociation rate | 22 |
blood collection | 22 |
also present | 22 |
response rates | 22 |
family donor | 22 |
poor outcomes | 22 |
clinical diagnosis | 22 |
patients whose | 22 |
particle loss | 22 |
prognostic factors | 22 |
air cleanliness | 22 |
transfusion protocol | 22 |
times per | 22 |
influenza infections | 22 |
tap water | 22 |
female donors | 22 |
regulatory networks | 22 |
operating characteristic | 22 |
endemic areas | 22 |
chronic obstructive | 22 |
antigen receptor | 22 |
ae ae | 22 |
minimal residual | 22 |
diagnostic test | 22 |
melphalan mg | 22 |
will provide | 22 |
cox proportional | 22 |
european countries | 22 |
causative agent | 22 |
palm civet | 22 |
two distinct | 22 |
sentinel surveillance | 22 |
significance level | 22 |
odds ratios | 22 |
maintenance therapy | 22 |
positive outcome | 22 |
component spectral | 22 |
potential role | 22 |
inhalation injury | 22 |
booking data | 22 |
iv agvhd | 22 |
two doses | 22 |
diagnostic criteria | 22 |
therapeutic potential | 22 |
group vs | 22 |
normal range | 22 |
graft source | 22 |
using different | 22 |
may improve | 22 |
neutrophil counts | 22 |
cognitive function | 22 |
underwent allo | 22 |
solid tumors | 21 |
data show | 21 |
structural basis | 21 |
virus detection | 21 |
infected animals | 21 |
rank test | 21 |
common variable | 21 |
icu survivors | 21 |
differential gene | 21 |
human seasonal | 21 |
takes place | 21 |
university school | 21 |
clinical manifestations | 21 |
blood safety | 21 |
starting point | 21 |
binding regions | 21 |
descriptive statistics | 21 |
task force | 21 |
male patients | 21 |
previous work | 21 |
may develop | 21 |
cells exposed | 21 |
last two | 21 |
sample preparation | 21 |
susceptible nodes | 21 |
ion channel | 21 |
virus entry | 21 |
chronic hepatitis | 21 |
treated cells | 21 |
rheumatoid arthritis | 21 |
glomerular filtration | 21 |
health services | 21 |
network topologies | 21 |
infective endocarditis | 21 |
staying home | 21 |
another study | 21 |
plasminogen activator | 21 |
cell differentiation | 21 |
alkaline phosphatase | 21 |
agvhd grade | 21 |
cognitive dysfunction | 21 |
surface water | 21 |
plasmodial activity | 21 |
household transmission | 21 |
achieved cr | 21 |
may vary | 21 |
muscle tremors | 21 |
vaccinated animals | 21 |
pcr products | 21 |
large numbers | 21 |
small molecule | 21 |
attenuated influenza | 21 |
made based | 21 |
effector cells | 21 |
social resources | 21 |
immune globulin | 21 |
glycan analysis | 21 |
serine proteases | 21 |
considered significant | 21 |
host range | 21 |
two genes | 21 |
health professionals | 21 |
sequence space | 21 |
differentially methylated | 21 |
contaminated water | 21 |
provide evidence | 21 |
wide variety | 21 |
performance characteristics | 21 |
total volume | 21 |
increasing social | 21 |
haploidentical transplantation | 21 |
clinical isolates | 21 |
delivery system | 21 |
treatment group | 21 |
two additional | 21 |
epidermal growth | 21 |
cell collection | 21 |
next step | 21 |
comparative study | 21 |
transplant recipient | 21 |
lymphocyte count | 21 |
previous findings | 21 |
drug target | 21 |
ns protein | 21 |
chronic conditions | 21 |
one study | 21 |
human plasma | 21 |
multivariable logistic | 21 |
inactivated vaccine | 21 |
cl protease | 21 |
animal model | 21 |
laboratory tests | 21 |
internal genes | 21 |
hydroxyl group | 21 |
lower levels | 21 |
increasing concentrations | 21 |
pedv challenge | 21 |
hemorrhagic shock | 21 |
filtration rate | 21 |
toxicity include | 21 |
must also | 21 |
positive cells | 21 |
human rhinoviruses | 21 |
liver transplantation | 21 |
surveillance data | 21 |
infl uence | 21 |
one hour | 21 |
developed acute | 21 |
defense compounds | 21 |
general hospital | 21 |
management system | 21 |
cns excitation | 21 |
health promotion | 21 |
glycan structures | 21 |
cytokine storm | 21 |
disease free | 21 |
venous pressure | 21 |
developed grade | 21 |
study cohort | 21 |
increasing structural | 20 |
hoc analysis | 20 |
new class | 20 |
molecular testing | 20 |
protein binding | 20 |
blood vessels | 20 |
positive ion | 20 |
received two | 20 |
national health | 20 |
masked palm | 20 |
therapeutic antibodies | 20 |
hand hygiene | 20 |
scd patients | 20 |
beneficial effects | 20 |
set infa | 20 |
systolic blood | 20 |
independent risk | 20 |
bat genomes | 20 |
urgent need | 20 |
cell recovery | 20 |
laboratory results | 20 |
helical coiled | 20 |
clinical response | 20 |
early phase | 20 |
two major | 20 |
sectional study | 20 |
hemagglutination inhibition | 20 |
sanger sequencing | 20 |
dead space | 20 |
biological processes | 20 |
gene families | 20 |
active cathepsin | 20 |
analgesic drugs | 20 |
stress symptoms | 20 |
small intestinal | 20 |
statin therapy | 20 |
patients using | 20 |
tumor cell | 20 |
human beings | 20 |
icu admissions | 20 |
intravenous immunoglobulin | 20 |
cd count | 20 |
immune deficiency | 20 |
significant predictor | 20 |
income countries | 20 |
colony stimulating | 20 |
isolation rate | 20 |
human sub | 20 |
potent inhibitors | 20 |
bk virus | 20 |
like receptors | 20 |
colon cancer | 20 |
molecular mechanisms | 20 |
related donors | 20 |
placental dna | 20 |
versus ae | 20 |
cardiovascular events | 20 |
mean score | 20 |
log tcid | 20 |
disease burden | 20 |
surgical icu | 20 |
proinflammatory cytokines | 20 |
short term | 20 |
control groups | 20 |
will continue | 20 |
multicenter study | 20 |
negative blood | 20 |
monoclonal anti | 20 |
negative impact | 20 |
nonsteroidal antiinflammatory | 20 |
dna binding | 20 |
open reading | 20 |
medium spiny | 20 |
catheter placement | 20 |
autosomal recessive | 20 |
cell densities | 20 |
target protein | 20 |
neutrophil recovery | 20 |
will require | 20 |
recent data | 20 |
mg per | 20 |
propensity score | 20 |
alveolar epithelial | 20 |
therapeutic plasma | 20 |
culture media | 20 |
chemical synthesis | 20 |
protein structure | 20 |
cholinesterase inhibitors | 20 |
free radical | 20 |
small animal | 20 |
low health | 20 |
adverse outcomes | 20 |
ae ml | 20 |
six months | 20 |
allowed us | 20 |
based analysis | 20 |
small amount | 20 |
also compared | 20 |
controlled study | 20 |
viral vector | 20 |
platelet products | 20 |
increased morbidity | 20 |
kg sq | 20 |
investigated whether | 20 |
across different | 20 |
hcv ns | 20 |
clinical setting | 20 |
delivery vectors | 20 |
national university | 20 |
shipping company | 20 |
fuzzy sets | 20 |
ug ml | 20 |
adaptive immune | 20 |
overall response | 20 |
two novel | 20 |
inventory management | 20 |
recreational water | 20 |
nasopharyngeal swabs | 20 |
matched donor | 20 |
studies showed | 20 |
multiple sclerosis | 20 |
samples tested | 20 |
decision matrix | 20 |
phase iii | 20 |
chicken embryos | 20 |
severe cgvhd | 20 |
groups according | 20 |
lactate levels | 20 |
national blood | 20 |
surgical removal | 20 |
tidal volumes | 20 |
antigenic drift | 20 |
shelf life | 20 |
viral production | 20 |
therapeutic option | 20 |
iron deficiency | 20 |
hiv protease | 20 |
parainfluenza virus | 20 |
treatment related | 20 |
recently published | 20 |
million people | 20 |
receptor antagonist | 20 |
cardiopulmonary bypass | 20 |
life support | 20 |
enzymatic activity | 20 |
serial dilutions | 20 |
tissue perfusion | 20 |
resistant virus | 20 |
boronic acid | 20 |
disease process | 20 |
life threatening | 20 |
postoperative period | 20 |
shear wave | 20 |
longer time | 20 |
intercostal space | 20 |
neuraminidase inhibitor | 20 |
less frequently | 20 |
turnaround time | 20 |
maximum likelihood | 20 |
labor supply | 20 |
potential risk | 20 |
pulmonary function | 20 |
transmission dynamics | 19 |
normal saline | 19 |
aa identities | 19 |
rift valley | 19 |
less toxic | 19 |
virus particles | 19 |
every patient | 19 |
hepatic failure | 19 |
salvage chemotherapy | 19 |
patients affected | 19 |
working group | 19 |
rapid test | 19 |
also seen | 19 |
may act | 19 |
highly sensitive | 19 |
hollow fiber | 19 |
small world | 19 |
virus strain | 19 |
rna extraction | 19 |
total returns | 19 |
implicit guarantee | 19 |
ecp treatment | 19 |
ards patients | 19 |
reference sequence | 19 |
mapped reads | 19 |
child care | 19 |
virus removal | 19 |
canadian blood | 19 |
fetal growth | 19 |
rhd gene | 19 |
statistical differences | 19 |
gut microbiota | 19 |
aki stage | 19 |
clotting factors | 19 |
commonly observed | 19 |
receptor site | 19 |
tight junctions | 19 |
large amounts | 19 |
hemodynamic parameters | 19 |
specific antibody | 19 |
different mechanisms | 19 |
backward bifurcation | 19 |
competing interests | 19 |
supplemental table | 19 |
healthcare utilization | 19 |
solved structure | 19 |
human genes | 19 |
methods used | 19 |
apheresis platelet | 19 |
control study | 19 |
human lung | 19 |
median dose | 19 |
sibling donors | 19 |
severity scores | 19 |
tm assay | 19 |
population immunity | 19 |
sequencing data | 19 |
shipping companies | 19 |
located within | 19 |
school children | 19 |
implicit government | 19 |
inflammatory mediators | 19 |
rate coefficients | 19 |
performance status | 19 |
spontaneous breathing | 19 |
shipping market | 19 |
acquired pneumonia | 19 |
different parts | 19 |
serologic testing | 19 |
insulin resistance | 19 |
guinea pig | 19 |
willebrand factor | 19 |
short period | 19 |
viral diseases | 19 |
obstructive pulmonary | 19 |
school students | 19 |
protein regulators | 19 |
cell receptor | 19 |
quantified using | 19 |
human cases | 19 |
diaphragmatic hernia | 19 |
cysteine proteinases | 19 |
mean values | 19 |
metabolic pathways | 19 |
antiviral activities | 19 |
antimicrobial therapy | 19 |
pdm viruses | 19 |
coding sequences | 19 |
lymphocytic choriomeningitis | 19 |
two children | 19 |
particularly important | 19 |
ray crystal | 19 |
new coronavirus | 19 |
low level | 19 |
virus yield | 19 |
fatality rate | 19 |
time course | 19 |
crystalloid fluid | 19 |
resonance imaging | 19 |
thalassemia major | 19 |
right ventricular | 19 |
circulating influenza | 19 |
study using | 19 |
may explain | 19 |
useful tool | 19 |
plasma units | 19 |
vaccinia virus | 19 |
cd kg | 19 |
university medical | 19 |
healthcare providers | 19 |
line development | 19 |
pediatric emergency | 19 |
results demonstrated | 19 |
tract disease | 19 |
ionic liquid | 19 |
expression value | 19 |
one third | 19 |
severe ards | 19 |
hierarchical clustering | 19 |
icu care | 19 |
viral antigen | 19 |
results confirm | 19 |
positive rate | 19 |
vitro studies | 19 |
nursing staff | 19 |
different aspects | 19 |
neonatal anthropometry | 19 |
year follow | 19 |
health problems | 19 |
streptococcus pneumoniae | 19 |
hotspot mutations | 19 |
control seizures | 19 |
serum potassium | 19 |
culture system | 19 |
toxic potential | 19 |
drug metabolism | 19 |
brain tissue | 19 |
data showed | 19 |
cell entry | 19 |
electron microscopy | 19 |
electron density | 19 |
lung function | 19 |
antiviral response | 19 |
canine parvovirus | 19 |
data shown | 19 |
naked rna | 19 |
improve patient | 19 |
kg cd | 19 |
prospectively collected | 19 |
gastroprotectant drugs | 19 |
classical swine | 19 |
post hoc | 19 |
neutralizing antibody | 19 |
may serve | 19 |
ischemic stroke | 19 |
newly food | 19 |
one dose | 19 |
significant changes | 19 |
high growth | 19 |
autologous sct | 19 |
less severe | 19 |
small amounts | 19 |
often associated | 19 |
curative treatment | 19 |
steroidal glycosides | 19 |
nuclear factor | 19 |
using two | 19 |
method based | 19 |
essential role | 19 |
spontaneous circulation | 19 |
false negative | 19 |
burn injury | 19 |
valley fever | 19 |
hordeum vulgare | 19 |
available online | 19 |
blood transfusions | 19 |
platelet inventory | 19 |
relatively high | 19 |
donor samples | 19 |
crp levels | 19 |
antigenic cartography | 19 |
mrna levels | 19 |
well established | 19 |
deferral rates | 19 |
human genome | 19 |
genes coding | 19 |
like particles | 19 |
cell membrane | 19 |
family history | 19 |
invasive ventilation | 18 |
serum lactate | 18 |
immune cell | 18 |
biological activities | 18 |
results may | 18 |
mortality due | 18 |
ifn antiviral | 18 |
digital literacy | 18 |
underwent hsct | 18 |
data bank | 18 |
weekly cases | 18 |
endotracheal intubation | 18 |
treat supportively | 18 |
blood ordering | 18 |
primary human | 18 |
extended data | 18 |
coping strategies | 18 |
fully understood | 18 |
one hand | 18 |